BACKGROUND:Early revascularization (ERV) is beneficial in the management of cardiogenic shock (CS) complicating myocardial infarction. The severity of CS varies widely, and identification of independent risk factors for outcome is needed. The effect of ERV on mortality in different risk strata is also unknown. We created a severity scoring system for CS and used it to examine the potential benefit of ERV in different risk strata using data from the SHOCK Trial and Registry. METHODS: Data from 1,217 patients (294 from the randomized trial and 923 from the registry) with CS due to pump failure were included in a Stage 1 severity scoring system using clinical variables. A Stage 2 scoring system was developed using data from 872 patients who had invasive hemodynamic measurements. The outcome was in-hospital mortality at 30 days. RESULTS: In-hospital mortality at 30 days was 57%. Multivariable modeling identified 8 risk factors (Stage 1): age, shock on admission, clinical evidence of end-organ hypoperfusion, anoxic brain damage, systolic blood pressure, prior coronary artery bypass grafting, noninferior myocardial infarction, and creatinine > or = 1.9 mg/dL (c-statistic = 0.74). Mortality ranged from 22% to 88% by score category. The ERV benefit was greatest in moderate- to high-risk patients (P = .02). The Stage 2 model based on patients with pulmonary artery catheterization included age, end-organ hypoperfusion, anoxic brain damage, stroke work, and left ventricular ejection fraction <28% (c-statistic = 0.76). In this cohort, the effect of ERV did not vary by risk stratum. CONCLUSIONS: Simple clinical predictors provide good discrimination of mortality risk in CS complicating myocardial infarction. Early revascularization is associated with improved survival across a broad range of risk strata. 2010 Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND: Early revascularization (ERV) is beneficial in the management of cardiogenic shock (CS) complicating myocardial infarction. The severity of CS varies widely, and identification of independent risk factors for outcome is needed. The effect of ERV on mortality in different risk strata is also unknown. We created a severity scoring system for CS and used it to examine the potential benefit of ERV in different risk strata using data from the SHOCK Trial and Registry. METHODS: Data from 1,217 patients (294 from the randomized trial and 923 from the registry) with CS due to pump failure were included in a Stage 1 severity scoring system using clinical variables. A Stage 2 scoring system was developed using data from 872 patients who had invasive hemodynamic measurements. The outcome was in-hospital mortality at 30 days. RESULTS: In-hospital mortality at 30 days was 57%. Multivariable modeling identified 8 risk factors (Stage 1): age, shock on admission, clinical evidence of end-organ hypoperfusion, anoxic brain damage, systolic blood pressure, prior coronary artery bypass grafting, noninferior myocardial infarction, and creatinine > or = 1.9 mg/dL (c-statistic = 0.74). Mortality ranged from 22% to 88% by score category. The ERV benefit was greatest in moderate- to high-risk patients (P = .02). The Stage 2 model based on patients with pulmonary artery catheterization included age, end-organ hypoperfusion, anoxic brain damage, stroke work, and left ventricular ejection fraction <28% (c-statistic = 0.76). In this cohort, the effect of ERV did not vary by risk stratum. CONCLUSIONS: Simple clinical predictors provide good discrimination of mortality risk in CS complicating myocardial infarction. Early revascularization is associated with improved survival across a broad range of risk strata. 2010 Mosby, Inc. All rights reserved.
Authors: Harold L Dauerman; Robert J Goldberg; Kami White; Joel M Gore; Immad Sadiq; Enrique Gurfinkel; Andrzej Budaj; Esteban Lopez de Sa; Jose Lopez-Sendon Journal: Am J Cardiol Date: 2002-10-15 Impact factor: 2.778
Authors: Rupert Fincke; Judith S Hochman; April M Lowe; Venu Menon; James N Slater; John G Webb; Thierry H LeJemtel; Gad Cotter Journal: J Am Coll Cardiol Date: 2004-07-21 Impact factor: 24.094
Authors: Rajendra H Mehta; Immad Sadiq; Robert J Goldberg; Joel M Gore; Alvaro Avezum; Frederick Spencer; Eva Kline-Rogers; Jeanna Allegrone; Karen Pieper; Keith A A Fox; Kim A Eagle Journal: Am Heart J Date: 2004-02 Impact factor: 4.749
Authors: Ovidiu Chioncel; Sean P Collins; Andrew P Ambrosy; Peter S Pang; Razvan I Radu; Elena-Laura Antohi; Josep Masip; Javed Butler; Vlad Anton Iliescu Journal: Am J Ther Date: 2019 Mar/Apr Impact factor: 2.688
Authors: Marc A Sintek; Mark Gdowski; Brian R Lindman; Michael Nassif; Kory J Lavine; Eric Novak; Richard G Bach; Scott C Silvestry; Douglas L Mann; Susan M Joseph Journal: J Card Fail Date: 2015-07-09 Impact factor: 5.712
Authors: Sanjeet Singh Avtaar Singh; Sudeep Das De; Francesco Nappi; Ahmed Al-Adhami; Yasser Hegazy; Jonathan Dalzell; Harikrishna Doshi; Andrew Sinclair; Philip Curry; Mark Petrie; Colin Berry; Nawwar Al-Attar Journal: J Thorac Dis Date: 2019-02 Impact factor: 2.895
Authors: Mohamed A Omer; Jose E Exaire; Jacob C Jentzer; Yader B Sandoval; Mandeep Singh; Charles R Cagin; Islam Y Elgendy; Tahir Tak Journal: Int J Angiol Date: 2021-02-12
Authors: Qussay Marashly; Iosif Taleb; Christos P Kyriakopoulos; Elizabeth Dranow; Tara L Jones; Anwar Tandar; Sean D Overton; Joseph E Tonna; Kathleen Stoddard; Omar Wever-Pinzon; Line Kemeyou; Antigone G Koliopoulou; Kevin S Shah; Kimiya Nourian; Tyler J Richins; Tyson S Burnham; Frederick G Welt; Stephen H McKellar; Jose Nativi-Nicolau; Stavros G Drakos Journal: Catheter Cardiovasc Interv Date: 2021-03-07 Impact factor: 2.692